Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 3/20 | 0.57 |
| ▸ | EGFR | P00533 | 5/20 | 0.55 |
| ▸ | ITK | Q08881 | 1/20 | 0.49 |
| ▸ | BCL6 | P41182 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13166189 | 0.87 | STK17A (0.53) | PIN1EGFRITKAURKABTK | |
| SCHEMBL12277575 | 0.86 | AURKA (0.51) | PIN1EGFRITKAURKASYK | |
| SCHEMBL266579 | 0.86 | STK17A (0.52) | PIN1EGFRBCL6AURKALRRK2 | |
| SCHEMBL13166258 | 0.85 | AURKA (0.50) | PIN1EGFRITKBCL6AURKA | |
| SCHEMBL7009208 | 0.84 | EGFR (0.45) | PIN1EGFRITKBCL6AURKA | |
| SCHEMBL9945499 | 0.84 | EGFR (0.64) | EGFRITKAURKASYKJAK2 | |
| SCHEMBL263864 | 0.84 | MEN1 (0.55) | EGFRSYKJAK2JAK3MEN1 | |
| SCHEMBL265574 | 0.84 | CCNA2 (0.52) | PIN1EGFRAURKASYKMEN1 | |
| SCHEMBL9923767 | 0.83 | SYK (0.51) | PIN1EGFRITKSYKBTK | |
| SCHEMBL19960624 | 0.83 | SYK (0.51) | PIN1EGFRITKSYKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008791-A1 | CHEMICAL COMPOUNDS | BORAH INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12358932-B2 | Chemical compounds | BORAH, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240368196-A1 | CHEMICAL COMPOUNDS | BORAH, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-114341145-B | Chemical compound | 博拉公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-114698370-A | Compounds and methods for treating cytokine release syndrome | 里格尔药品股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| EP-3994142-A1 | CHEMICAL COMPOUNDS | Borah, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114341145-A | Chemical compound | 博拉公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021003501-A1 | CHEMICAL COMPOUNDS | Boragen, Inc. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2021003501-A1 | CHEMICAL COMPOUNDS | Boragen, Inc. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| EP-1268444-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| CN-1211373-C | 2,4-di (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | disclosed |
| US-6649608-B2 | Cyclin-dependent serine/threonine and focal adhesion kinase inhibitors | ASTRAZENECA AB (SE) | 2003-11-18 | — | — | US | disclosed |
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| CN-1406230-A | 2,4-di (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-03-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | PIN1 154/4885EGFR 1981/4885ITK 2697/4885 |
| US-20260008791-A1 | CHEMICAL COMPOUNDS | JAK3, JAK2, JAK1 | PIN1 4310/4885EGFR 530/4885ITK 880/4885 |
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | CDK2, CCNI, CDK1 | PIN1 4044/4885EGFR 489/4885ITK 579/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PIN1 154/4885EGFR 1981/4885ITK 2697/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | PIN1 1403/4885EGFR 460/4885ITK 317/4885 |
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | PIN1 1149/4885EGFR 529/4885ITK 637/4885 |
| US-20240368196-A1 | CHEMICAL COMPOUNDS | PDE4A, PDE4B, SYK | PIN1 3734/4885EGFR 1266/4885ITK 317/4885 |
| US-12358932-B2 | Chemical compounds | PDE4A, PDE4B, SYK | PIN1 3734/4885EGFR 1266/4885ITK 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.